CXCL11 and neoplasm: Oncolytic viruses expressing proinflammatory cytokines and antigens, such as IL-12 (HSV-1 M032) and CXCL11 (oAd-CXCL11), as well as viral particles expressing antibodies against immunosuppressive receptors including CD47 (OV-αCD47-G1) were able to elicit a strong tumour immune response and enhance the therapeutic efficacy of CAR T-cells in vivo [260–263].